fremanezumab
Trade name: Ajovy
mAbapproved
Approved
Sep 14, 2018
Fremanezumab, sold under the brand name Ajovy, is a medication used to prevent migraines. It is given by subcutaneous injection. — Wikipedia
Clinical trial activity
32 trials · 11 clinical orgs · 1 marketing orgs
Phase 1
2
Phase 2
19
Phase 3
15
Phase 4
7
Earliest trial started Oct 1, 2013 (NCT01991509)
Timeline
Indications
Approved for
Studied for
- Brain Diseases · Phase 4
- CADASIL · Phase 2
- Cluster Headache · Phase 3
- Cystitis, Interstitial · Phase 2
- Fibromyalgia · Phase 2
- Major Depressive Disorder · Phase 4
- Migraine Disorders · Phase 4
- Migraine with Aura · Phase 4
- Migraine without Aura · Phase 4
- Pharmacokinetics · Phase 1
- Post-Traumatic Headache · Phase 2
- Sleep Wake Disorders · Phase 4
Mechanism of action
- Calcitonin gene-related peptideANTAGONIST
calcitonin gene-related peptide
- Protein S100-A12INHIBITOR
S100A12 inhibitor
Approval history
- approvedPriority reviewSep 14, 2018
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaFremanezumab ↗
- NCATSPF8K38CG54 ↗
- ChEMBLCHEMBL4297756 ↗
Also known as
- fremanezumab
- fremanezumab-vfrm
- lbr-101
- tev-48125
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06173661 | Phase 4 | Jan 31, 2024 | Harvard University, Teva |
| NCT06244823 | Phase 4 | Mar 1, 2023 | Sanidad de Castilla y Leon, University of Valladolid |
| NCT05724771 | Phase 4 | Jan 26, 2023 | Chicago Headache Center |
| NCT05458011 | Phase 3 | Aug 23, 2022 | Teva |
| NCT05284019 | Phase 4 | Mar 4, 2022 | Lundbeck |
| NCT04693533 | Phase 4 | Aug 1, 2021 | Harvard University, Teva |
| NCT04334408 | Phase 2 | Jan 31, 2021 | Mayo Clinic |
| NCT04461795 | Phase 4 | Dec 1, 2020 | Clinvest |
| NCT04447729 | Phase 2 | Oct 15, 2020 | Teva |
| NCT04530110 | Phase 3 | Sep 16, 2020 | Teva |
| NCT04547179 | N/A | Sep 15, 2020 | Manhattan Beach Orthodontics |
| NCT04464707 | Phase 3 | Jul 30, 2020 | Teva |
| NCT04458857 | Phase 3 | Jul 16, 2020 | Teva |
| NCT04355117 | Phase 3 | May 31, 2020 | Otsuka |
| NCT04041284 | Phase 4 | Aug 10, 2019 | Teva |
| NCT03965091 | Phase 2 | May 31, 2019 | Teva |
| NCT03303105 | Phase 3 | Jan 4, 2018 | Otsuka |
| NCT03303092 | Phase 2/Phase 3 (Phase 3) | Dec 19, 2017 | Otsuka |
| NCT03303079 | Phase 2/Phase 3 (Phase 3) | Dec 19, 2017 | Otsuka |
| NCT03347188 | Phase 2 | Nov 17, 2017 | Teva |
Showing 20 of 32 trials
Page 1 / 2
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Teva | For profit | 22 | 20 | 5 | 2013 |
| Otsuka | For profit | 4 | 4 | 1 | 2017 |
| Harvard University | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Chicago Headache Center | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Clinvest | For profit | 1 | 1 | 1 | 2020 |
| Lundbeck | For profit | 1 | 1 | 1 | 2022 |
| Manhattan Beach Orthodontics | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2021 |
| NCGS, Inc. | For profit | 1 | 0 | 1 | 2014 |
| Sanidad de Castilla y Leon | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Valladolid | Academic/Hospital | 1 | 1 | 1 | 2023 |
11 organizations
Page 1 / 1